Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report

Growth Hormone and IGF Research

Volumn 17, Issue 1, 2007, Pages 54-57

  Shevah, O ^a   Laron, Z ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

GH gene deletion; GHRH receptor defect; IGF I; Laron syndrome

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PREVENTION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FAMILY HISTORY; FAMILY STUDY; FEMALE; GENE DELETION; HORMONE RESISTANCE; HUMAN; LARON SYNDROME; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEFICIENCY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC DISEASES, INBORN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE;

EID: 33847198926     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.10.007     Document Type: Article

References (19)

1. Kappel C.C., Velez-Yanguas M.C., Hirschfeld S., and Helman L.J. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 54 (1994) 2803-2807
2. Yee D., Favoni R.E., Lebovic G.S., et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J. Clin. Invest. 86 (1990) 1806-1814
3. Singleton J.R., Randolph A.E., and Feldman E.L. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res. 56 (1996) 4522-4529
4. Minniti C.P., Tsokos M., Newton Jr. W.A., and Helman L.J. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol. 101 (1994) 198-203
5. Werner H., Re G.G., Drummond I.A., et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc. Natl. Acad. Sci. USA 90 (1993) 5828-5832
6. Werner H., and LeRoith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit. Rev. Oncog. 8 (1997) 71-92
7. Jernstrom H., Chu W., Vesprini D., et al. Genetic factors related to racial variation in plasma levels of insulin like growth factor-1: Implications for premenopausal breast cancer risk. Mol. Genet. Metab. 72 (2001) 144-154
8. Pollak M.N. Insulin-like growth factors and neoplasia. In: Le Roith D., Goode J., and Bock G. (Eds). Biology of IGF-I: Its Interaction with Insulin in Health and Malignant States. Novartis Foundation Symposium vol. 262 (2004), John Wiley & Sons, Ltd., Chichester 84-107
9. Schoen R.E., Weissfeld J.L., Kuller L.H., et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 129 (2005) 464-475
10. Weber M.M., Fottner C., Liu S.B., Jung M.C., Engelhardt D., and Baretton G.B. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95 (2002) 2086-2095
11. DeLellis K., Ingles S., Kolonel L., et al. IGF-I genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br. J. Cancer 88 (2003) 277-282
12. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4 (2004) 579-591
13. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity). The personal experience 1958-2003. J. Clin. Endocrinol. Metab. 89 (2004) 1031-1044
14. Rosenfeld R.G., Rosenbloom A.L., and Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr. Rev. 15 (1994) 369-390
15. Rosenbloom A.L., and Guevara-Aguirre J. Lessons from the genetics of Laron syndrome. Trends Endocrinol. Metab. 9 (1998) 276-283
16. Laron Z., Pertzelan A., and Mannhimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism?. Isr. J. Med. Sci. 2 (1966) 152-155
17. Wang Z., Prins G.S., Coschigano K.T., et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146 (2005) 5188-5196
18. Zhang H., and Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert. Opin. Inv. Drug. 13 (2004) 1569-1577
19. Jenkins P.J., Mukherjee A., and Shalet S.M. Does growth hormone cause cancer?. Clin. Endocrinol. (Oxf.) 64 (2006) 115-121